Bexson Biomedical Announces Expansion to Treat Major Depression with Wearable Ketamine Formulation

SANTA BARBARA, Calif.: SANTA BARBARA, Calif., Nov. 18, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company developing subcutaneous treatment platforms for pain management and mental health disorders, today announced it has received pre-IND guidance from the FDA for its lead ketamine compound for acute pain management. With this milestone...

Click to view original post